PDCD1 and neoplasm: Tumor mutation burden (TMB) refers to the relative number of mutations in given tumor tissue; if more nonsynonymous mutations are present in the tumor, more neoantigens emerge, and the PD-1/PD-L1 axis becomes involved in blocking the immune response, thus affecting the response of tumor cells to ICIs.